Robert Maki

39PUBLICATIONS
214CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|Jun 08, 2026
Cancer Chemoimmunotherapy: Time Will Tell.

|May 04, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

|Apr 30, 2026
Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

|Apr 16, 2026
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.

|Feb 12, 2026
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand

Pageof 7

Frequent Collaborators

9 joint publications

Sujana Movva

8 joint publications

Sandra P D'Angelo

7 joint publications

Evan Rosenbaum

7 joint publications

Cristina R Antonescu